Citius Oncology (CTOR) to Release Quarterly Earnings on Friday

Citius Oncology (NASDAQ:CTOR) is anticipated to issue its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings data on Tuesday, December 23rd. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06).

Citius Oncology Stock Performance

Shares of CTOR opened at $1.11 on Friday. The company has a market cap of $97.99 million, a price-to-earnings ratio of -3.26 and a beta of 3.09. The business’s fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $1.53. Citius Oncology has a 12 month low of $0.55 and a 12 month high of $6.19. The company has a current ratio of 0.56, a quick ratio of 0.11 and a debt-to-equity ratio of 0.08.

Hedge Funds Weigh In On Citius Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after acquiring an additional 36,758 shares during the period. Jane Street Group LLC bought a new position in Citius Oncology in the second quarter valued at about $465,000. Bank of America Corp DE boosted its position in Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after purchasing an additional 8,411 shares during the last quarter. Citadel Advisors LLC purchased a new position in Citius Oncology in the third quarter worth about $36,000. Finally, Armistice Capital LLC bought a new stake in shares of Citius Oncology during the 3rd quarter valued at about $15,582,000. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.